Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-707-7 | CAS number: 124-64-1
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
THPC is classified as structurally alerting by virtue of its natural electrophilicity. However, THPC is negative in the bacterial reverse mutation assay. THPC was tested and found to be clearly positive in threein-vitrotests for genotoxicity: a test for chromosomal aberrations in CHO cells, a test for mutations at the thymidine kinase (TK) locus in mouse lymphoma L5178Y cells, and a test for sister-chromatid exchanges (SCE) in CHO cells.
No indications for genotoxicity were found with a close related substance (THPS) in the followingin-vivotests: two tests for micronuclei (MN-PCE) and for chromosomal aberrations (CA) in bone marrow cells of oral treated mice and two tests for micronuclei (MN-PCE) and for chromosomal aberrations (CA) in bone marrow of dermal treated mice. Further, no indications for genotoxicity was found with a commercial preparation of THPC (Proban CC) in the mouse micronucleustest according current protocol.
Short description of key information:
In vitro: positive (CA, MLA, SCE)
In vivo: negative (MN, CA)
Carinogenicity: negative (2 oral, dermal)
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
THPC was found to be a genotoxic compound when tested for this endpoint in vitro. However, no genotoxic effects were found in relevant in-vivo studies. This marked difference may be attributed to the electrophilic reactivity / complete biotransformation of the THP ion and the rapid irreversible binding to proteins. Apparently no parent compound reaches the bone marrow in which the formation of micronuclei is studied. The positive in-vitro effects can then be explained by the fact that under in-vitro conditions degradation and/or binding are not occurring to an extent large enough to prevent the parent compounds to reach the DNA. The lack of in-vivo genotoxicity complies with the absence of treatment-related carcinogenicity in the 2-year gavage studies with rats and mice (NTP 1987). Moreover, the open literature provides a dermal carcinogenicity study in which no local or other carcinogenic effects were observed (Van Duuren 1978).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
